series-c-plus
Stage
2018
Founded
3
Investors
About
Vivet Therapeutics develops liver-directed gene therapies for rare genetic diseases, focusing on AAV-based treatments and technology to reduce neutralizing antibodies that limit gene therapy efficacy.
Explore Vivet Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.